Cytokine Storm: A Suicidal Immune Response to Novel Corona Virus

Jignakumari J. Gohil; Chiragkumar J. Gohil

doi:10.34257/GJMRBVOL21IS1PG31

Authors

Jignakumari J. Gohil
Chiragkumar J. Gohil

Keywords:

sars-cov-2; covid-19; cytokine storm; hyperimmune response; ards; multi-organ failure; drugrepurposing

Abstract

SARS-CoV-2 virus is responsible for the COVID-19 disease in patients. Only 15-20 % of COVID-19 patients have developed severe pulmonary symptoms and illness, which are fatal to patients. Hyperimmune response to the SARS-CoV-2 virus by the host's immune system causes the release and over production of certain kinds of inflammatory mediators and cytokines. And it results in the cytokine storm. Cytokine storm produces the hyper inflammatory reaction, which deteriorates the cells and tissue. This type of immune response is host killing and suicidal response to the SARS-CoV-2 virus by the host. This suicidal response ultimately leads to lung damage, respiratory tract pneumonia, ARDS, multi-organ failure at a later stage and ultimately death. Hence, it needs to suppress the hyper-functioning of the immune system to inhibit the cytokine release and cytokine storm. Anti-inflammatory and immuno-modulatory drugs can be repurposed to manage the cytokine storm and hyper-immune response. Inhibition and management of the host's suicidal immune response and cytokine storm, could be life-saving and reduce the mortality rate in COVID-19 patients.

Downloads

How to Cite

Cytokine Storm: A Suicidal Immune Response to Novel Corona Virus. (2021). Global Journal of Medical Research, 21(B1), 31-37. https://doi.org/10.34257/GJMRBVOL21IS1PG31

Download Citation

References

C Gohil, M Noolvi (2020) Novel Corona Virus and Its Druggable Targets. 1(3), 51-53.

Dawei Wang, Bo Hu, Chang Hu, Fangfang Zhu, Xing Liu, Jing Zhang, Binbin Wang, Hui Xiang, Zhenshun Cheng, Yong Xiong, Yan Zhao, Yirong Li, Xinghuan Wang, Zhiyong Peng (2020) Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. 323(11), 1061.

D Sen, S Mandal, A Biswas, D Dastider, B Mahanti (2020) Corona Is Culprit of Ridiculous Offensive Nonsense Air. 9, 1-16.

M Tay, C Poh, L Renia, P Macary, Lfp Ng (2020) The trinity of COVID-19: immunity, inflammation and intervention. 1-12.

Chuan Qin, Luoqi Zhou, Ziwei Hu, Shuoqi Zhang, Sheng Yang, Yu Tao, Cuihong Xie, Ke Ma, Ke Shang, Wei Wang, Dai-Shi Tian (2020) Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. 71(15), 762-768.

Qing Ye, Bili Wang, Jianhua Mao (2020) The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. 80(6), 607-613.

Kao‐jean Huang, Ih‐jen Su, Michel Theron, Yi‐chun Wu, Shu‐kuan Lai, Ching‐chuan Liu, Huan‐yao Lei (2005) An interferon‐γ‐related cytokine storm in SARS patients. 75(2), 185-194.

M Prajapat, P Sarma, N Shekhar, P Avti, S Sinha, H Kaur, S Kumar, A Bhattacharyya, H Kumar, S Bansal, B Medhi (2020) Drug targets for corona virus: A systematic review. 52, 56-65.

K Yuen, S Wong (2005) Human infection by avian influenza A H5N1. 11, 189-199.

Francesca Coperchini, Luca Chiovato, Laura Croce, Flavia Magri, Mario Rotondi (2020) The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. 53, 25-32.

Pratik Sinha, Michael Matthay, Carolyn Calfee (2020) Is a "Cytokine Storm" Relevant to COVID-19?. 180(9), 1152.

Thomas Braciale, Young Hahn (2013) Immunity to viruses. 255(1), 5-12.

M Thompson, J Kaminski, E Kurt-Jones, K Fitzgerald (2011) Pattern recognition receptors and the innate immune response to viral infection. 3, 920-940.

Subramanian Loganathan, Sandeep Athalye, Shashank Joshi (2020) Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. 20(9), 1025-1031.

Y Mehta, S Dixit, K Zirpe, A Ansari (2020) Cytokine Storm in Novel Coronavirus Disease (COVID-19): Expert Management Considerations. 24, 429-434.

M Prarthana, S Kalagi (2015) Middle East Respiratory Syndrome: An Overview. 5, 422-429.

Dina Ragab, Haitham Salah Eldin, Mohamed Taeimah, Rasha Khattab, Ramy Salem (2020) The COVID-19 Cytokine Storm; What We Know So Far. 11, 1-4.

C Dinarello (2009) Immunological and inflammatory functions of the interleukin-1 family. 27, 519-550.

Nicole Schmitz, Michael Kurrer, Martin Bachmann, Manfred Kopf (2005) Interleukin-1 Is Responsible for Acute Lung Immunopathology but Increases Survival of Respiratory Influenza Virus Infection. 79(10), 6441-6448.

Jennifer Tisoncik, Marcus Korth, Cameron Simmons, Jeremy Farrar, Thomas Martin, Michael Katze (2012) Into the Eye of the Cytokine Storm. 76(1), 16-32.

B Goodman (null) Some bacteria residing in the human body may contribute to the COVID-19 "cytokine storm".

M Zhao (2020) Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. 55, 1-3.

Joseph Geraci, Bronnil Hawill (2020) Repurposing Dupilumab May Treat Advanced COVID-19 Patients With Severe Acute Respiratory Syndrome By Mitigating Cytokine Storm.

A Jain (2020) COVID-19 and lung pathology. 63, 171-172.

T Ishikawa (2012) Clinical preparedness for cytokine storm induced by the highly pathogenic H5N1 influenza virus. 3, 1000-e131.

Semmannan Kalaiyarasu, Manoj Kumar, Dhanapal Senthil Kumar, Sandeep Bhatia, Sandeep Dash, Sushant Bhat, Rohit Khetan, Shanmugasundaram Nagarajan (2016) Highly pathogenic avian influenza H5N1 virus induces cytokine dysregulation with suppressed maturation of chicken monocyte‐derived dendritic cells. 60(10), 687-693.

Mark Roschewski, Michail Lionakis, Jeff Sharman, Joseph Roswarski, Andre Goy, M Monticelli, Michael Roshon, Stephen Wrzesinski, Jigar Desai, Marissa Zarakas, Jacob Collen, Keith Rose, Ahmed Hamdy, Raquel Izumi, George Wright, Kevin Chung, Jose Baselga, Louis Staudt, Wyndham Wilson (2020) Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. 5(48).

Jaume Alijotas-Reig, Enrique Esteve-Valverde, Cristina Belizna, Albert Selva-O'callaghan, Josep Pardos-Gea, Angela Quintana, Arsene Mekinian, Ariadna Anunciacion-Llunell, Francesc Miró-Mur (2020) Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. 19(7), 102569.

Eva Schrezenmeier, Thomas Dörner (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. 16(3), 155-166.

Christian Devaux, Jean-Marc Rolain, Philippe Colson, Didier Raoult (2020) New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. 55(5), 105938.

Q Ruan, K Yang, W Wang, L Jiang, J Song (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. 46, 846-848.